bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
[' psa', 'bimekizumab', ' ada ']
#l02 #acr22 bimekizumab ph3 in psa: meaningful clinical improvement, improved mtss, no new safety signals. wk 52 acr50: 53.0% pbo/bkz, 54.5% bkz, 50.0% ada; mda 53.7% pbo/bkz, 55.0% bkz, 52.9% ada . mtss change from baseline 0.5): 87.3% pbo/bkz, 89.3% bkz, 94.1% ada 
Rheumatologist at Scarsdale Medical Group, Runner, Traveler Opinions are my own